|
🐜
|
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
35 auth.
M. Lebwohl,
B. Strober,
A. Menter,
K. Gordon,
J. Węgłowska,
L. Puig,
K. Papp,
L. Spelman,
D. Toth,
F. Kerdel,
A. Armstrong,
G. Stingl,
A. Kimball,
H. Bachelez,
Jashin J. Wu,
...
J. Crowley,
R. Langley,
T. Blicharski,
C. Paul,
J. Lacour,
S. Tyring,
L. Kircik,
S. Chimenti,
K. Callis Duffin,
J. Bagel,
J. Koo,
G. Aras,
Joanne Li,
Wenjie Song,
Cassandra E. Milmont,
Yifei Shi,
N. Erondu,
P. Klekotka,
B. Kotzin,
A. Nirula
|
9 |
2015 |
9
🐜
|
|
🐜
|
A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis
18 auth.
K. Papp,
K. Reich,
Carle Paul,
A. Blauvelt,
W. Baran,
C. Bolduc,
D. Toth,
R. Langley,
J. Cather,
A. Gottlieb,
...
D. Thąci,
J. Krueger,
C. Russell,
Cassandra E. Milmont,
Joanne Li,
P. Klekotka,
G. Kricorian,
A. Nirula
|
8 |
2016 |
8
🐜
|
|
🐜
|
Clinical meaningfulness of complete skin clearance in psoriasis.
15 auth.
B. Strober,
K. Papp,
M. Lebwohl,
K. Reich,
C. Paul,
A. Blauvelt,
K. Gordon,
Cassandra E. Milmont,
H. Viswanathan,
Joanne Li,
...
L. Pinto,
D. Harrison,
G. Kricorian,
A. Nirula,
P. Klekotka
|
6 |
2016 |
6
🐜
|
|
🐜
|
Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.
8 auth.
D. Pariser,
C. Leonardi,
K. Gordon,
A. Gottlieb,
S. Tyring,
K. Papp,
...
Joanne Li,
S. Baumgartner
|
6 |
2012 |
6
🐜
|
|
🐜
|
Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory
8 auth.
K. Gordon,
Alexa B. Kimball,
D. Chau,
H. Viswanathan,
Joanne Li,
D. Revicki,
...
G. Kricorian,
B. Ortmeier
|
5 |
2014 |
5
🐜
|
